Can China and the U.S. work together to cure cancer?
In the early afternoon of June 5, 2017, at the annual American Society of Clinical Oncology (ASCO) conference, hundreds of the world’s leading cancer researchers, pharmaceutical firms and biotech investors focused their attention on a virtually unknown Chinese firm called Legend Biotech.
At that time, the U.S. company Johnson & Johnson’s $10.6 billion research and development budget amounted to $3 billion more than all Chinese pharmaceutical firms combined. But despite hailing from a
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Washington’s $370 billion Inflation Reduction Act was seen as a generational opportunity for miners in the U.S. as well as mineral rich trading partners. But almost two years later, the North American mining industry is in crisis and no closer to chipping away at China's dominance. What went wrong?
The academic explains why we need to look beyond the actions of the Chinese government to understand how and why China is shaping countries in the region.
Navigate China's Business Landscape with Confidence.